Nalaganje...
Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill
Anti-CD 20 therapies have found significant uses in multiple sclerosis (MS). Based singularly on the accumulated evidence with the use of rituximab (RTX; Rituxan, Genentech, and Biogen) in neuroimmunological diseases, ocrelizumab (OCR; Ocrevus, Genentech) was developed as a treatment option for MS a...
Shranjeno v:
| izdano v: | Drug Target Insights |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5661702/ https://ncbi.nlm.nih.gov/pubmed/29123374 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1177392817737515 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|